Pfizer CEO Albert Bourla delivers a speech in Thessaloniki, Greece on October 12, 2021. (Photo: Sakis Mitrolidis/AFP via Getty Images)
Jul 11, 2022
Public health advocates on Monday said a newly-reported discussion between Pfizer executives and investors illustrated exactly why efforts to protect people's health must not be seen as a driver of profits, as the company's views on waning Covid-19 mitigation tactics came to light.
As Kaiser Health News reported last week in an article about the pharmaceutical company's outsized influence over the federal government as the U.S. navigates the ongoing coronavirus pandemic, executives spoke openly in a May 3 earnings call with investors about the benefits of lifted mask mandates and rising demand for Paxlovid, the company's antiviral medication.
"Medical and economic systems motivated by profit can't be incentivized to create lasting health."
"We also see that the social--the removal of the mask mandate, the social distancing requirements that have been removed," said Angela Hwang, president of Pfizer's biopharmaceuticals group. "People are going to get out there. We know with all of that, infections are going to increase, and that's the role that Paxlovid can play."
The company has agreed to sell 20 million five-day courses of the medication, which is prescribed to Covid-19 patients who are at high risk for severe disease, paying $530 for each course.
Pfizer appears to be seeing a significant return on investment after spending more than $25 million to lobby the federal government to pass legislation to protect and promote its products since the pandemic began. The company doubled its revenue in 2021 from the previous year, raking in $81.3 billion after introducing Paxlovid and widely distributing its Covid-19 vaccine.
The company's apparent enthusiasm for continuing that upward trend--even it means thousands of people continue to be sickened and hospitalized and hundreds die each day as the virus continues to mutate and spread--reminded one blogger of pharmaceutical companies creating and profiting from the opioid epidemic.
"Prevention is key and should be the humane top priority, not lining pockets," said Chloe Humbert, author of a newsletter about the pandemic.
Public health experts have warned in recent months that the lifting of mask mandates for public transportation, including planes, and in other public places is likely to increase transmission of the virus.
Nearly 100% of the U.S. population lives in areas where transmission of Covid-19 is currently classified as "high" by the Centers for Disease Control and Prevention (CDC), according to the agency's transmission map.
Bradford William Davis, an investigative reporter for Business Insider, said the earnings call was noteworthy because it included comments by people in positions of power acknowledging that Covid is spreading "as a direct result of removing Covid protections like masks."
Mikael Dolsten, Pfizer's chief scientific officer, also noted in the earnings call that immunocompromised people "may carry this virus for a very, very long time" and need repeated courses of Paxlovid.
"And we see that area as a real new opportunity growth area for Paxlovid to do very well, where you may need to take multiple courses over a year or even treat with extended duration," Dolsten told investors.
The executives' comments reminded Dr. Steven Thrasher, author of The Viral Underclass, of a funeral home director he interviewed "who longed for the early AIDS years because it was better for his business."
"Medical and economic systems motivated by profit can't be incentivized to create lasting health," said Thrasher. "And if the various Covid vaccines had been open sourced, [other] countries could have vaccinated people and lowered the chances for mutations."
"It is obscene that people may die or suffer from long Covid or painful monkeypox lesions or go blind just for the profit of a few people," he added.
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, The U.S. is on a fast track to authoritarianism like nothing I've ever seen. Meanwhile, corporate news outlets are utterly capitulating to Trump, twisting their coverage to avoid drawing his ire while lining up to stuff cash in his pockets. That's why I believe that Common Dreams is doing the best and most consequential reporting that we've ever done. Our small but mighty team is a progressive reporting powerhouse, covering the news every day that the corporate media never will. Our mission has always been simple: To inform. To inspire. And to ignite change for the common good. Now here's the key piece that I want all our readers to understand: None of this would be possible without your financial support. That's not just some fundraising cliche. It's the absolute and literal truth. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. Our Summer Campaign is now underway, and there’s never been a more urgent time for Common Dreams to be as vigilant as possible. Will you donate now to help power the nonprofit, independent reporting of Common Dreams? Thank you for being a vital member of our community. Together, we can keep independent journalism alive when it’s needed most. - Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Public health advocates on Monday said a newly-reported discussion between Pfizer executives and investors illustrated exactly why efforts to protect people's health must not be seen as a driver of profits, as the company's views on waning Covid-19 mitigation tactics came to light.
As Kaiser Health News reported last week in an article about the pharmaceutical company's outsized influence over the federal government as the U.S. navigates the ongoing coronavirus pandemic, executives spoke openly in a May 3 earnings call with investors about the benefits of lifted mask mandates and rising demand for Paxlovid, the company's antiviral medication.
"Medical and economic systems motivated by profit can't be incentivized to create lasting health."
"We also see that the social--the removal of the mask mandate, the social distancing requirements that have been removed," said Angela Hwang, president of Pfizer's biopharmaceuticals group. "People are going to get out there. We know with all of that, infections are going to increase, and that's the role that Paxlovid can play."
The company has agreed to sell 20 million five-day courses of the medication, which is prescribed to Covid-19 patients who are at high risk for severe disease, paying $530 for each course.
Pfizer appears to be seeing a significant return on investment after spending more than $25 million to lobby the federal government to pass legislation to protect and promote its products since the pandemic began. The company doubled its revenue in 2021 from the previous year, raking in $81.3 billion after introducing Paxlovid and widely distributing its Covid-19 vaccine.
The company's apparent enthusiasm for continuing that upward trend--even it means thousands of people continue to be sickened and hospitalized and hundreds die each day as the virus continues to mutate and spread--reminded one blogger of pharmaceutical companies creating and profiting from the opioid epidemic.
"Prevention is key and should be the humane top priority, not lining pockets," said Chloe Humbert, author of a newsletter about the pandemic.
Public health experts have warned in recent months that the lifting of mask mandates for public transportation, including planes, and in other public places is likely to increase transmission of the virus.
Nearly 100% of the U.S. population lives in areas where transmission of Covid-19 is currently classified as "high" by the Centers for Disease Control and Prevention (CDC), according to the agency's transmission map.
Bradford William Davis, an investigative reporter for Business Insider, said the earnings call was noteworthy because it included comments by people in positions of power acknowledging that Covid is spreading "as a direct result of removing Covid protections like masks."
Mikael Dolsten, Pfizer's chief scientific officer, also noted in the earnings call that immunocompromised people "may carry this virus for a very, very long time" and need repeated courses of Paxlovid.
"And we see that area as a real new opportunity growth area for Paxlovid to do very well, where you may need to take multiple courses over a year or even treat with extended duration," Dolsten told investors.
The executives' comments reminded Dr. Steven Thrasher, author of The Viral Underclass, of a funeral home director he interviewed "who longed for the early AIDS years because it was better for his business."
"Medical and economic systems motivated by profit can't be incentivized to create lasting health," said Thrasher. "And if the various Covid vaccines had been open sourced, [other] countries could have vaccinated people and lowered the chances for mutations."
"It is obscene that people may die or suffer from long Covid or painful monkeypox lesions or go blind just for the profit of a few people," he added.
Public health advocates on Monday said a newly-reported discussion between Pfizer executives and investors illustrated exactly why efforts to protect people's health must not be seen as a driver of profits, as the company's views on waning Covid-19 mitigation tactics came to light.
As Kaiser Health News reported last week in an article about the pharmaceutical company's outsized influence over the federal government as the U.S. navigates the ongoing coronavirus pandemic, executives spoke openly in a May 3 earnings call with investors about the benefits of lifted mask mandates and rising demand for Paxlovid, the company's antiviral medication.
"Medical and economic systems motivated by profit can't be incentivized to create lasting health."
"We also see that the social--the removal of the mask mandate, the social distancing requirements that have been removed," said Angela Hwang, president of Pfizer's biopharmaceuticals group. "People are going to get out there. We know with all of that, infections are going to increase, and that's the role that Paxlovid can play."
The company has agreed to sell 20 million five-day courses of the medication, which is prescribed to Covid-19 patients who are at high risk for severe disease, paying $530 for each course.
Pfizer appears to be seeing a significant return on investment after spending more than $25 million to lobby the federal government to pass legislation to protect and promote its products since the pandemic began. The company doubled its revenue in 2021 from the previous year, raking in $81.3 billion after introducing Paxlovid and widely distributing its Covid-19 vaccine.
The company's apparent enthusiasm for continuing that upward trend--even it means thousands of people continue to be sickened and hospitalized and hundreds die each day as the virus continues to mutate and spread--reminded one blogger of pharmaceutical companies creating and profiting from the opioid epidemic.
"Prevention is key and should be the humane top priority, not lining pockets," said Chloe Humbert, author of a newsletter about the pandemic.
Public health experts have warned in recent months that the lifting of mask mandates for public transportation, including planes, and in other public places is likely to increase transmission of the virus.
Nearly 100% of the U.S. population lives in areas where transmission of Covid-19 is currently classified as "high" by the Centers for Disease Control and Prevention (CDC), according to the agency's transmission map.
Bradford William Davis, an investigative reporter for Business Insider, said the earnings call was noteworthy because it included comments by people in positions of power acknowledging that Covid is spreading "as a direct result of removing Covid protections like masks."
Mikael Dolsten, Pfizer's chief scientific officer, also noted in the earnings call that immunocompromised people "may carry this virus for a very, very long time" and need repeated courses of Paxlovid.
"And we see that area as a real new opportunity growth area for Paxlovid to do very well, where you may need to take multiple courses over a year or even treat with extended duration," Dolsten told investors.
The executives' comments reminded Dr. Steven Thrasher, author of The Viral Underclass, of a funeral home director he interviewed "who longed for the early AIDS years because it was better for his business."
"Medical and economic systems motivated by profit can't be incentivized to create lasting health," said Thrasher. "And if the various Covid vaccines had been open sourced, [other] countries could have vaccinated people and lowered the chances for mutations."
"It is obscene that people may die or suffer from long Covid or painful monkeypox lesions or go blind just for the profit of a few people," he added.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.